{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699994716043520.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1182/blood-2008-02-140665"}},{"identifier":{"@type":"URI","@value":"http://ashpublications.org/blood/article-pdf/112/4/1005/1454883/zh801608001005.pdf"}}],"dc:title":[{"@value":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome–positive leukemia"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title>\n               <jats:p>Although imatinib, a BCR-ABL tyrosine kinase inhibitor, is used to treat acute Philadelphia chromosome–positive (Ph+) leukemia, it does not prevent central nervous system (CNS) relapses resulting from poor drug penetration through the blood-brain barrier. Imatinib and dasa-tinib (a dual-specific SRC/BCR-ABL kinase inhibitor) were compared in a preclinical mouse model of intracranial Ph+ leukemia. Clinical dasatinib treatment in patients with CNS Ph+ leukemia was assessed. In preclinical studies, dasatinib increased survival, whereas imatinib failed to inhibit intracranial tumor growth. Stabilization and regression of CNS disease were achieved with continued dasa-tinib administration. The drug also demonstrated substantial activity in 11 adult and pediatric patients with CNS Ph+ leukemia. Eleven evaluable patients had clinically significant, long-lasting responses, which were complete in 7 patients. In 3 additional patients, isolated CNS relapse occurred during dasatinib therapy; and in 2 of them, it was caused by expansion of a BCR-ABL–mutated dasatinib-resistant clone, implying selection pressure exerted by the compound in the CNS. Dasatinib has promising therapeutic potential in managing intracranial leukemic disease and substantial clinical activity in patients who experience CNS relapse while on imatinib therapy. This study is registered at ClinicalTrials.gov as CA180006 (#NCT00108719) and CA180015 (#NCT00110097).</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699994716043399","@type":"Researcher","foaf:name":[{"@value":"Kimmo Porkka"}],"jpcoar:affiliationName":[{"@value":"Hematology Research Unit, Biomedicum Helsinki, Helsinki, Finland;"},{"@value":"Departments of Clinical Chemistry and Medicine/Hematology, and"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043394","@type":"Researcher","foaf:name":[{"@value":"Perttu Koskenvesa"}],"jpcoar:affiliationName":[{"@value":"Hematology Research Unit, Biomedicum Helsinki, Helsinki, Finland;"},{"@value":"Departments of Clinical Chemistry and Medicine/Hematology, and"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043526","@type":"Researcher","foaf:name":[{"@value":"Tuija Lundán"}],"jpcoar:affiliationName":[{"@value":"Hematology Research Unit, Biomedicum Helsinki, Helsinki, Finland;"},{"@value":"HUSLAB, Department of Molecular Pathology, Helsinki University Central Hospital, Helsinki, Finland;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043529","@type":"Researcher","foaf:name":[{"@value":"Johanna Rimpiläinen"}],"jpcoar:affiliationName":[{"@value":"North-Karelia Central Hospital, Joensuu, Finland;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043396","@type":"Researcher","foaf:name":[{"@value":"Satu Mustjoki"}],"jpcoar:affiliationName":[{"@value":"Hematology Research Unit, Biomedicum Helsinki, Helsinki, Finland;"},{"@value":"Departments of Clinical Chemistry and Medicine/Hematology, and"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043523","@type":"Researcher","foaf:name":[{"@value":"Richard Smykla"}],"jpcoar:affiliationName":[{"@value":"Bristol-Myers Squibb Research and Development, Princeton, NJ;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043525","@type":"Researcher","foaf:name":[{"@value":"Robert Wild"}],"jpcoar:affiliationName":[{"@value":"OSI Pharmaceuticals, In Vivo Pharmacology, Boulder, CO;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043393","@type":"Researcher","foaf:name":[{"@value":"Roger Luo"}],"jpcoar:affiliationName":[{"@value":"Bristol-Myers Squibb Research and Development, Princeton, NJ;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043530","@type":"Researcher","foaf:name":[{"@value":"Montserrat Arnan"}],"jpcoar:affiliationName":[{"@value":"ICO-Hospital Duran i Reynals, Barcelona, Spain;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043398","@type":"Researcher","foaf:name":[{"@value":"Benoit Brethon"}],"jpcoar:affiliationName":[{"@value":"Hôpital Saint-Louis, Pediatric Hematology, Paris, France;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043395","@type":"Researcher","foaf:name":[{"@value":"Lydia Eccersley"}],"jpcoar:affiliationName":[{"@value":"Ealing Hospital, Southall, United Kingdom;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043524","@type":"Researcher","foaf:name":[{"@value":"Henrik Hjorth-Hansen"}],"jpcoar:affiliationName":[{"@value":"Department of Hematology, St Olavs Hospital and Department of Molecular Medicine and Cancer Research, Norwegian University of Science and Technology, Trondheim, Norway;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043397","@type":"Researcher","foaf:name":[{"@value":"Martin Höglund"}],"jpcoar:affiliationName":[{"@value":"Uppsala University Hospital, Uppsala, Sweden;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043522","@type":"Researcher","foaf:name":[{"@value":"Hana Klamova"}],"jpcoar:affiliationName":[{"@value":"Institute of Hematology and Blood Transfusion, Prague, Czech Republic;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043402","@type":"Researcher","foaf:name":[{"@value":"Håvar Knutsen"}],"jpcoar:affiliationName":[{"@value":"Akershus University Hospital, Lorenskog, Norway;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043400","@type":"Researcher","foaf:name":[{"@value":"Suhag Parikh"}],"jpcoar:affiliationName":[{"@value":"Duke University Medical Center, Pediatric Blood and Marrow Transplant Program, Durham, NC;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043520","@type":"Researcher","foaf:name":[{"@value":"Emmanuel Raffoux"}],"jpcoar:affiliationName":[{"@value":"Hôpital Saint-Louis, Paris, France;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043528","@type":"Researcher","foaf:name":[{"@value":"Franz Gruber"}],"jpcoar:affiliationName":[{"@value":"University of Tromsø, Tromsø, Norway;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043532","@type":"Researcher","foaf:name":[{"@value":"Finella Brito-Babapulle"}],"jpcoar:affiliationName":[{"@value":"Ealing Hospital, Southall, United Kingdom;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043401","@type":"Researcher","foaf:name":[{"@value":"Hervé Dombret"}],"jpcoar:affiliationName":[{"@value":"Hôpital Saint-Louis, Paris, France;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043533","@type":"Researcher","foaf:name":[{"@value":"Rafael F. Duarte"}],"jpcoar:affiliationName":[{"@value":"ICO-Hospital Duran i Reynals, Barcelona, Spain;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043531","@type":"Researcher","foaf:name":[{"@value":"Erkki Elonen"}],"jpcoar:affiliationName":[{"@value":"Departments of Clinical Chemistry and Medicine/Hematology, and"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043527","@type":"Researcher","foaf:name":[{"@value":"Ron Paquette"}],"jpcoar:affiliationName":[{"@value":"University of California-Los Angeles;"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043521","@type":"Researcher","foaf:name":[{"@value":"C. Michel Zwaan"}],"jpcoar:affiliationName":[{"@value":"Erasmus Medical Center (MC), Pediatric Oncology, Rotterdam, The Netherlands; and"},{"@value":"The Innovative Therapies for Children with Cancer (ITCC) Consortium, Paris, France"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994716043392","@type":"Researcher","foaf:name":[{"@value":"Francis Y. F. Lee"}],"jpcoar:affiliationName":[{"@value":"Bristol-Myers Squibb Research and Development, Princeton, NJ;"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00064971"},{"@type":"EISSN","@value":"15280020"}],"prism:publicationName":[{"@value":"Blood"}],"dc:publisher":[{"@value":"American Society of Hematology"}],"prism:publicationDate":"2008-08-15","prism:volume":"112","prism:number":"4","prism:startingPage":"1005","prism:endingPage":"1012"},"reviewed":"false","url":[{"@id":"http://ashpublications.org/blood/article-pdf/112/4/1005/1454883/zh801608001005.pdf"}],"createdAt":"2008-05-14","modifiedAt":"2019-11-18","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004231520692352","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Dasatinib induces autophagy in mice with Bcr-Abl-positive leukemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004239210622336","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Dasatinib is effective against optic nerve infiltration of Philadelphia chromosome-positive acute lymphoblastic leukemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142797040384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617556571136","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Dasatinib–Blinatumomab for Ph-Positive ALL"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593776325376","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute"}]},{"@id":"https://cir.nii.ac.jp/crid/1361412891987052544","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Myodesopsia is a symptom of central nervous system blast crisis in chronic myeloid leukemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204876277504","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A Rare Monocytic Crisis of Chronic Myelogenous Leukemia Presenting with Unusual Extramedullary Manifestations and an Atypical (14;22)(q24;q11.2) Translocation in the Bone Marrow"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205422501504","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"移植片対白血病効果を保ちつつベクロメタゾン腸溶性製剤で腸管移植片対宿主病抑制を得た急性期慢性骨髄性白血病"},{"@language":"en","@value":"Oral beclomethasone dipropionate successfully controls gastrointestinal graft-versus-host disease without affecting systemic graft-versus-leukemia effect in blastic phase chronic myeloid leukemia"}]},{"@id":"https://cir.nii.ac.jp/crid/1390289564740000512","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"<i>BCR/ABL1</i>-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1182/blood-2008-02-140665"},{"@type":"CROSSREF","@value":"10.1007/s12185-016-2137-5_references_DOI_NLT28MpTmSBTjmk5cAOU6g4aD4D"},{"@type":"CROSSREF","@value":"10.3109/10428194.2010.509453_references_DOI_NLT28MpTmSBTjmk5cAOU6g4aD4D"},{"@type":"CROSSREF","@value":"10.1371/journal.pntd.0008361_references_DOI_NLT28MpTmSBTjmk5cAOU6g4aD4D"},{"@type":"CROSSREF","@value":"10.1056/nejmc2033785_references_DOI_NLT28MpTmSBTjmk5cAOU6g4aD4D"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.8617-16_references_DOI_NLT28MpTmSBTjmk5cAOU6g4aD4D"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.7066-21_references_DOI_NLT28MpTmSBTjmk5cAOU6g4aD4D"},{"@type":"CROSSREF","@value":"10.1007/s12185-021-03156-0_references_DOI_NLT28MpTmSBTjmk5cAOU6g4aD4D"},{"@type":"CROSSREF","@value":"10.1016/j.lrr.2019.03.001_references_DOI_NLT28MpTmSBTjmk5cAOU6g4aD4D"},{"@type":"CROSSREF","@value":"10.7889/hct.4.82_references_DOI_NLT28MpTmSBTjmk5cAOU6g4aD4D"}]}